Pro-drugs of all non-steroidal anti-inflammatories with free acid function derivatized with an ester group which have the general structural formula given below (I) where A is: aspirin diflunisal benorylate ibufenac diclofenac indomethacin sulindac ketorolac ibuprofen naproxen ketoprofen fenoprofen flurbiprofen mefenamic acid meclof enamic acid flufenamic acid niflumic acid and where in the ester group R can be a sugar (amongst which aldose or ketose pentose or esose selected from a group of D- ...

Composition comprises (a) at least one first compound comprising celecoxib etoricoxib lumiracoxib parecoxib rofecoxib valdecoxib valicoxib and (b) at least one second compound comprising: e.g. indoprofen ibuproxam ketoprofen ketorolac loxoprofen naproxen naproxen sodium oxaprozin pirprofen suprofen tiaprofenic acid and alminoprofen; salicylamide and salicyl salicylate; aceclofenac acemetacin and alclofenac; mefenamic acid flufenamic acid and meclofenamic acid; ampyrone azapropazone and clofezone...

A sustained release dosage form for delivering a pharmaceutically active agent to a patient in need thereof, comprising: (1) a semipermeable wall defining a cavity and including an exit orifice formed or formable therein, and (2) an erodible solid contained within the cavity and located adjacent to the exit orifice, said erodible solid comprising a binder, a disintegrant and between 70-90 weight percent of a pharmaceutically active agent, wherein the erodible solid is released from the dosage fo...

Pro-drugs of all non-steroidal anti-inflammatories with free acid function derivatized with an ester group which have the general structural formula given below (I) where A is: aspirin diflunisal benorylate ibufenac diclofenac indomethacin sulindac ketorolac ibuprofen naproxen ketoprofen fenoprofen flurbiprofen mefenamic acid meclof enamic acid flufenamic acid niflumic acid and where in the ester group R can be a sugar (amongst which aldose or ketose pentose or esose selected from a group of D- ...

Pro-drugs of all non-steroidal anti-inf lammatories with free acid function derivatized with an ester group which have the general structural formula given below (I) where A is: aspirin diflunisal benorylate ibufenac diclofenac indomethacin sulindac ketorolac ibuprofen naproxen ketoprofen fenoprofen flurbiprofen mefenamic acid meclof enamic acid flufenamic acid niflumic acid and where in the ester group R can be a sugar (amongst which aldose or ketose pentose or esose selected from a group of D-...

The patent application relates to chemical compounds with a basic structure selected from salicylic acid acetylsalicylic acid APHS (o-acetoxyphenylhept-2-inylsulfid) salen ligands diflunisal salsalate benorylate phenylalkanylcarbon acids (particularly fenoprofen ibuprofen ketoprofen flurbiprofen naproxen tolmetin sulindac indomethacin diclofenac carprofen etodolac ketorolac) oxicam inhibitors (particularly Tenoxicam Prioxicam Meloxicam) anthranilic acids: (particularly mefenamic acid meclofenami...

Die Patentanmeldung betrifft chemische Verbindungen mit einer Grundstruktur ausgewählt aus Salicylsäure Acetylsalicylsäure APHS (o-Acetoxyphenylhept-2-inylfulfid) Salenliganden Diflunisal Salsalat Benorylat Phenylalkanylcarbonsäuren (insbesondere Fenoprofen Ibuprofen Ketoprofen Flurbiprofen Naproxen Tolmetin Sulindac Indomethacin Diclofenac Carprofen Etodolac Ketorolac) Oxicaminhibitoren (insbesondere Tenoxicam Prioxicam Meloxicam) Anthranil-Säuren (insbesondere Mefenaminsäure Meclofenamin...

Organic compounds, such as precursors for aryl ethylamines such as ephedrine, aryl propylamines such as fluoxetine and propionic acid derivatives such as ibuprofen, naproxen and fenoprofen, are subjected to a yeast mediated reduction conducted in the absence of a solvent. The yeast is moistened with water and contacted with the organic compound. The yeast may then be contacted with an organic solvent to dissolve the product of the reaction into the solvent, and a solid/liquid separation used to ...